Avantor, Inc. Profile Avatar - Palmy Investing

Avantor, Inc.

Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials…
Chemicals - Specialty
US, Radnor [HQ]

FA

Fundamental Analysis · Most Recent Quarter

It is important to understand the FA Algorithm and the criterias before valuing it as a top-tier resource.

Read Rationale
Framework:
Valuation 14% Weak
Profitability n.A. n.A.
Fin. Growth 67% Positive
Leverage & Liquidity 17% Weak
Per Share Metrics 0% Bad
Fin. Health n.A. n.A.
Fundamentals

Valuation

Metric Q4 Q1 Δ in %
EV/EBITDA 13.75 82.51 72.53
Graham Fair Price -21.27 3.97 5.04
PEG 72.18 -1.74 -6.27
Price/Book 9.10 3.21 2.94
Price/Cash Flow 108.40 160.11 76.83
Prices/Earnings 80.75 70.84 39.19
Price/Sales 13.67 10.19 8.96
Price/FCF 108.40 160.11 76.83
Naive Interpretation member
01 - Valuation · Weak
Fundamentals

Profitability

Metric Q4 Q1 Δ in %
Gross Profit Margin 2.58 0.34 0.33
Operating Margin -5.16 0.10 0.11
ROA -37.67 < 0.005 < 0.005
ROE 0.02 0.01 -39.64
ROIC 0.01 0.01 -14.91
Naive Interpretation member
02 - Profitability · Not Interpreted
Fundamentals

Financial Growth

Metric Q4 Q1 Δ in %
Debt QOQ -0.04 -0.02 -142.52
Dividends QOQ 0.00 0.00 0.00
EBIT QOQ -0.13 -0.08 41.17
EPS QOQ -0.06 -0.41 -549.60
FCF QOQ 0.04 -0.47 1029.43
Revenue QOQ < 0.005 -0.02 1551.35
Naive Interpretation member
03 - Financial Growth · Positive
Fundamentals

Leverage & Liquidity

Metric Q4 Q1 Δ in %
Assets Turnover n.A. n.A. n.A.
Days Inventory Outstanding (DIO) 64.67 65.77 1.69
Days Sales Outstanding (DSO) 60.09 60.53 0.73
Inventory Turnover 1.39 1.37 -1.66
Debt/Capitalization 0.51 0.50 -2.69
Quick Ratio 0.97 0.96 -0.72
Naive Interpretation member
04 - Leverage & Liquidity · Weak
Fundamentals

Per Share Metrics

Metric Q4 Q1 Δ in %
Book Value 7.77 7.87 1.34
Cash 0.41 0.37 -9.74
Capex -0.07 -0.05 31.59
Free Cash Flow 0.30 0.16 -46.95
Revenue 2.55 2.48 -2.74
Naive Interpretation member
05 - Per Share Metrics · Bad
Fundamentals

Financial Health

Metric Q4 Q1 Δ in %
Current Ratio 1.61 1.61 -0.08
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA 18.47 18.91 2.40
Naive Interpretation Member
06 - Financial Health · Weak
End of AVTR's Analysis
CIK: 1722482 CUSIP: 05352A100 ISIN: US05352A1007 LEI: - UEI: -
Secondary Listings
AVTR has no secondary listings inside our databases.